Related Experiment Videos
Hypertension and lipids
1Department of Hypertension, National Institute of Cardiology, Warsaw, Poland.
Insights
Hypertension and hyperlipidaemia are significant cardiovascular disease risk factors. Antihypertensive drugs impact lipid metabolism, influencing treatment strategies for better patient outcomes.
Area of Science:
- Cardiology
- Metabolic Disorders
- Pharmacology
Background:
- Hypertension and hyperlipidaemia are prevalent, interrelated risk factors for cardiovascular disease.
- These conditions, particularly when co-occurring as Familial Dyslipidaemic Hypertension, significantly elevate atherosclerosis and mortality risks.
- Essential hypertension is increasingly recognized as a metabolic disorder linked to lipid metabolism derangements.
Purpose of the Study:
- To investigate the relationship between hypertension and hyperlipidaemia.
- To examine the impact of antihypertensive medications on lipid metabolism.
- To support the concept of individualized hypertension therapy based on metabolic profiles.
Main Methods:
- Review of epidemiological data on hypertension and hyperlipidaemia prevalence.
- Analysis of existing research on the effects of various antihypertensive drugs on lipid profiles.
- Exploration of pathogenetic links between hypertension and lipid metabolism.
Main Results:
- High prevalence of both hypertension (20-40%) and hyperlipidaemia (60-70%) in the Polish adult population.
- Significantly higher prevalence of hyperlipidaemia in hypertensive individuals compared to normotensive subjects.
- Antihypertensive drugs exhibit varied effects on lipid metabolism, with some being unfavorable, neutral, or beneficial.
Conclusions:
- Hypertension and hyperlipidaemia are critical, interconnected cardiovascular risk factors.
- Antihypertensive therapy must consider metabolic effects, particularly on lipids, for comprehensive patient care.
- Individualized treatment approaches are essential to manage hypertension and its metabolic comorbidities effectively, aiming to prevent cardiovascular complications.
Abstract:
Hypertension and hyperlipidaemia are closely interrelated. Both belong to the most important risk factors of cardiovascular disease, with special emphasis on the premature development of atherosclerosis and its complications. The prevalence of both hypertension and hyperlidaemia is high; in the Polish adult population, like in many other countries, it amounts to 20-40% and 60-70%, respectively. The prevalence of hyperlipidaemia in patients with essential hypertension is much higher than in the normotensive subjects and both abnormalities markedly increase the risk of cardiovascular disease. In so called Familial Dyslipidaemic Hypertension, the 16 years mortality rates were 4 times higher than in subjects with dyslipidaemia and hypertension as single risk factors. The present data point to essential hypertension as a metabolic disorder, which may have some pathogenetic links with the derangement of lipid metabolism. According to the recent results, only about 15% of all hypertensives do not exhibit metabolic disturbances. One of the most important topics in this respect is the influence of antihypertensive drugs on metabolic factors, with special reference to lipid metabolism. Some of these drugs may have unfavourable action on lipid variables, while other are neutral or even beneficial. These differences may have great impact on the therapeutic approach to hypertensive patients and form the basis for the concept of individualized therapy of hypertension. The goal of antihypertensive therapy is not only to lower the blood pressure but also to influence all other factors which may be significant for the prognosis. Only such an integrated approach may prevent atherosclerotic complications and reduce the risk of cardiovascular morbidity and mortality.